AILBRY - Article Search
Serach over 250 million academic articles from all areas of study
Results for 'Xichun Hu'
:
A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer
Publication Year: 2017
DOI: https://doi.org/10.18632/oncotarget.20478
Abstract:
Add to Library
Authors:
Yannan Zhao
Chengcheng Gong
Zhonghua Wang
Jian Zhang
Leiping Wang
Sheng Zhang
Jun Cao
Zhonghua Tao
Ting Li
Biyun Wang
Xichun Hu
Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
Publication Year: 2017
DOI: https://doi.org/10.18632/oncotarget.16336
Abstract:
Add to Library
Authors:
Chengcheng Gong
Yannan Zhao
Biyun Wang
Xichun Hu
Zhonghua Wang
Jian Zhang
Sheng Zhang
GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer
Publication Year: 2017
DOI: https://doi.org/10.18632/oncotarget.22450
Abstract:
Add to Library
Authors:
Jian Zhang
Ying Wu
Xichun Hu
Biyun Wang
Leiping Wang
Sheng Zhang
Jun Cao
Zhonghua Wang
Abstract GS3-04: GS3-04 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the Phase III CAPItello-291 trial
Publication Year: 2023
DOI: https://doi.org/10.1158/1538-7445.sabcs22-gs3-04
Abstract:
Add to Library
Authors:
Nicholas C. Turner
Mafalda Oliveira
Sacha J. Howell
Florence Dalenc
Javier Cortés
Henry Gómez
Xichun Hu
Komal Jhaveri
Sibylle Loibl
Serafín Morales
Zbigniew Nowecki
Meena Okera
Yeon H. Park
Masakazu Toi
Lyudmila Zhukova
Chris Yan
Gaia Schiavon
Andrew Foxley
Hope S. Rugo
Abstract OT-03-09: Trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator’s choice of chemotherapy in patients with hormone receptor-positive (HR+), HER2 low metastatic breast cancer whose disease has progressed on endocrine therapy in the metastatic setting: A randomized, global phase 3 trial (DESTINY-Breast06)
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.sabcs20-ot-03-09
Abstract:
Add to Library
Authors:
Aditya Bardia
Carlos H. Barrios
Rebecca Dent
Xichun Hu
Joyce O’Shaughnessy
Kan Yonemori
Annie Darilay
Sarice Boston
Yufan Liu
Gargi Patel
Giuseppe Curigliano
Abstract P1-18-16: A phase 1 study of ARX788, a HER2-targeting antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer
Publication Year: 2020
DOI: https://doi.org/10.1158/1538-7445.sabcs19-p1-18-16
Abstract:
Add to Library
Authors:
Xichun Hu
Jian Zhang
Dongmei Ji
Gang Xia
Yanping Ji
Gaozhun Xiong
Xuejun Liang
Updated results and biomarker analyses from the phase I trial of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.
Publication Year: 2022
DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.1037
Abstract:
Add to Library
Authors:
Xichun Hu
Jian Zhang
Rujiao Liu
Shuiping Gao
Junyan Wu
Ying Wang
Yanrong Hao
Junyou Ge
Qing Yan
Shuli Yi
Qixian Yang
Huajing Rao
Juanjuan Yuan
Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study
Publication Year: 2016
DOI: https://doi.org/10.18632/oncotarget.9331
Abstract:
Add to Library
Authors:
Binghe Xu
Xichun Hu
Hong Zheng
Xiaojia Wang
Qingyuan Zhang
Shude Cui
Donggeng Liu
Ning Liao
Rongcheng Luo
Qiang Sun
Shiying Yu
Abstract PS10-57: A randomized, multicenter, open-label phase II/III study of ARX788 vs Lapatinib and Capecitabine in patients with HER2-positive locally advanced or metastatic breast cancer (ZMC-ARX788-211)
Publication Year: 2021
DOI: https://doi.org/10.1158/1538-7445.sabcs20-ps10-57
Abstract:
Add to Library
Authors:
Xichun Hu
Jian Zhang
Leiping Wang
Gang Xia
Yanping Ji
Gaozhun Xiong
Xuejun Liang
Sulan Yao
Feng Tian
PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC).
Publication Year: 2023
DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.1046
Abstract:
Add to Library
Authors:
Jian Zhang
Yanchun Meng
Biyun Wang
Xinhong Wu
Hongmei Zheng
Li Cai
Wenyan Chen
Leiping Wang
Jun Cao
Zhonghua Tao
Ting Li
Ni Sujie
Zhengyan Yu
Xuesong Chen
Qiang Peng
Xin Hu
Wenqing Yao
Xichun Hu
Abstract GS3-02: Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer
Publication Year: 2022
DOI: https://doi.org/10.1158/1538-7445.sabcs21-gs3-02
Abstract:
Add to Library
Authors:
Binghe Xu
Min Yan
Fei Ma
Xichun Hu
Jifeng Feng
Quchang Ouyang
Zhongsheng Tong
Huiping Li
Qingyuan Zhang
Tao Sun
Xian Wang
Yongmei Yin
Ying Cheng
Wěi Li
Xiaoyu Zhu
Chunxia Chen
Jianjun Zou
Abstract GS1-06: A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer
Publication Year: 2022
DOI: https://doi.org/10.1158/1538-7445.sabcs21-gs1-06
Abstract:
Add to Library
Authors:
Binghe Xu
Qingyuan Zhang
Xichun Hu
Qing Li
Tao Sun
Wěi Li
Quchang Ouyang
Jingfen Wang
Zhongsheng Tong
Min Yan
Huiping Li
Xiaohua Zeng
Changping Shan
Xian Wang
Xi Yan
Jian Zhang
Yue Zhang
Jiani Wang
Liang Zhang
Ying Lin
Jifeng Feng
Qianjun Chen
Jian Huang
Yongkui Lu
Hongsheng Li
Jinsheng Wu
Jing Cheng
Yanrong Hao
Cuizhi Geng
Min Lu
Yanping Li
Xi Chen
Lihua Song
Xueying Wu
Changlu Hu
Xinhong Wu
Xiaojia Wang
Yueyin Pan
Yuehong Cui
Guohua Yu
Sanyuan Sun
Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study
Publication Year: 2020
DOI: https://doi.org/10.21037/tbcr-20-25
Abstract:
Add to Library
Authors:
Min Yan
Li Bian
Xichun Hu
Qingyuan Zhang
Quchang Ouyang
Jifeng Feng
Yongmei Yin
Tao Sun
Zhongsheng Tong
Xiaojia Wang
Herui Yao
Jianjun Zou
Xiaoyu Zhu
Zefei Jiang
Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis
Publication Year: 2022
DOI: https://doi.org/10.1186/s13045-022-01297-1
Abstract:
Add to Library
Authors:
Yizhao Xie
Biyun Wang
Yannan Zhao
Zhong-Hua Tao
Ye Wang
Guangliang Chen
Xichun Hu
Abstract P2-13-43: Preclinical and early clinical safety and pharmacokinetics data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2 positive metastatic breast cancer
Publication Year: 2022
DOI: https://doi.org/10.1158/1538-7445.sabcs21-p2-13-43
Abstract:
Add to Library
Authors:
Jian Zhang
Nicholas P. McAndrew
Wenlei Yu
Xiaomei Pan
Mei Wang
Xichun Hu
Found 94 results in 0.055 seconds
What is Boolean Searches
Including any of the words AND
, OR
, or NOT
in any of your searches will enable
boolean search. Those words must be UPPERCASE . You can use this in all searches, including using
the search parameter, and using search filters.
This allows you to craft complex queries using those boolean operators along with parentheses and quotation marks.
Surrounding a phrase with quotation marks will search for an exact match of that phrase, after stemming and
stop-word removal (be sure to use double quotation marks — "
). Using parentheses will specify order of
operations for the boolean operators. Words that are not separated by one of the boolean operators will be
interpreted as AND
.
Behind the scenes, the boolean search is using Elasticsearch's query string query on the searchable fields (such as
title, abstract, and fulltext for works; see each individual entity page for specifics about that entity). Wildcard
and fuzzy searches using *
, ?
or ~
are not allowed; these characters will be
removed from any searches. These searches, even when using quotation marks, will go through the same cleaning as
described above, including stemming and removal of stop words.
Example Search
Search for works that mention "elmo"
and "sesame street"
, but not the words
"cookie"
or "monster"
:
"elmo" AND "sesame street" NOT "cookie" NOT "monster"